https://www.diabesityrounds.com/a/next-generation-incretins-early-signals-beyond-semaglutide-not-yet-like-for-likeDiabesity Roundsen2026-11-01T02:03:18.256ZNext-generation incretins: early signals beyond semaglutide, not yet like for likehttps://www.diabesityrounds.com/a/lower-gdm-diagnostic-thresholds-doubled-diagnoses-without-better-short-term-outcDiabesity Roundsen2026-10-31T20:17:14.826ZLower GDM diagnostic thresholds doubled diagnoses without better short-term outcomeshttps://www.diabesityrounds.com/a/oral-orforglipron-reduced-bodyweight-more-than-placebo-at-72-weeks-in-japanese-aDiabesity Roundsen2026-10-31T20:02:33.017ZOral orforglipron reduced bodyweight more than placebo at 72 weeks in Japanese adults